Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

February 23, 2010 updated by: Alcon Research
The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in these children

Study Overview

Study Type

Interventional

Enrollment (Actual)

132

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Waco, Texas, United States, 76712
        • Niran Amar, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 months to 3 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient must be at least 2 years of age and less than 6 years of age on Day 1;
  • Parent/legal guardian must be willing and able to give written informed consent and must provide this consent for the study;
  • Patient must have a positive case history of allergic rhinitis symptoms and at least one documented positive skin test within the 5 years prior to Day 1 of the following type: skin prick test, intradermal test or RAST test(radioallergosorbent test) for an allergen (≥ 3 mm wheal greater than diluent after skin prick testing; ≥ 7 mm wheal greater than the diluent after intradermal testing; or positive level 2 or greater after RAST testing);
  • Patient and parent/caregiver must be willing and able to make required study visits;
  • Patient and parent/caregiver must be able to follow instructions;
  • Nasal exam must confirm absence of significant anatomic abnormalities, infection, bleeding, and mucosal ulcerations at Screening and prior to administration of test article at the Day 1 Visit. A finding of 'present' for any of these parameters disqualifies the patient from the study, regardless of clinical relevance.

Exclusion Criteria:

  • The need for chronic or intermittent use of any prescription or over-the-counter nasal spray during the study period;
  • Use of any form of olopatadine (e.g., PATANOL®, PATADAY™, PATANASE®) within 7 days of Day 1;
  • Current or recent (within the last 14 days) use of any drugs/drug classes or combinations thereof that may prolong the QT interval;
  • Patients with a history or evidence of nasolacrimal drainage system malfunction or abnormality that may interfere with the results of the study;
  • Concurrent disease that might complicate or interfere with the investigation or evaluation of the study medications (such as rhinitis medicamentosa or large obstructive nasal polyps);
  • Patients with syndromes associated with midfacial deformities or other anatomic nasal deformity that may interfere with the patient's participation in the study, as identified by physical or nasal examination at Screening or Day 1;
  • Diagnosis of acute sinusitis within 30 days of Day 1 or diagnosis of chronic rhinosinusitis within one year of Day 1;
  • Congestion that would, in the opinion of the investigator, interfere with successful nasal drug administration/absorption (in either nostril);
  • Upper or lower respiratory infection within 14 days of Day 1;
  • Asthma, with the exception of intermittent asthma as outlined in Section 18.5, from the Stepwise Approach for Managing Asthma in Children 0-4 Years of Age, and Stepwise Approach for Managing Asthma in Children 5-11 Years of Age (5);
  • Current or recent (< 6 months) history of severe, unstable, or uncontrolled neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal disease, or evidence of other diseases at the physical examination conducted at the Screening Visit, which in the opinion of the Investigator would preclude the safe participation of the patient in the study;
  • Hypersensitivity to olopatadine, benzalkonium chloride, or any component of the test articles;
  • History or current infection of HIV (Human Immunodeficiency Virus), hepatitis B or C or A, as indicated by the patient's parent or legal guardian response on the HIV/Hepatitis survey;
  • Relatives of study site staff or other individuals who would have access to the clinical study protocol;
  • A family member or any individual residing in the same household of a patient that is currently enrolled in the study;
  • Participation in any other investigational study within 30 days before entry into this study (Day 1), or concomitantly with this study;
  • Clinically relevant abnormal vital signs (pulse rate, average systolic and diastolic blood pressure) at Screening or Day 1. The ranges below have been designated as normal for the study. Inclusion of patients with values outside of these normal ranges is at the discretion of the study investigator;

Normal Cardiovascular Ranges

  • Systolic Blood Pressure - 86 to 116 mmHg (millimeters mercury)
  • Diastolic Blood Pressure -50 to 78 mmHg
  • Pulse - 75 to 130 bpm (beats per minute)

In addition, the Alcon Medical Monitor and/or Principal Investigator may declare any patient ineligible for the study based upon sound medical reasons.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Olopatadine Hydrochloride Nasal Spray 0.6%
one spray in each nostril twice daily for 2 weeks
Placebo Comparator: 2
Olopatadine Hydrochloride Nasal Spray Vehicle
one spray in each nostril twice daily for 2 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Anatomic Nasal Exam Abnormalities
Time Frame: Day 1 (Baseline) to Exit
The appearance in a participant of any of the following from Baseline: anatomic abnormalities, evidence of infection, bleeding, and/or ulcerations of the mucosa
Day 1 (Baseline) to Exit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Paul Ratner, MD, Sylvana Research Associates
  • Principal Investigator: Niran Amar, MD
  • Principal Investigator: Sheri Byrd, MD, Spartanburg Medical Center
  • Principal Investigator: Albert Finn, MD, National Allergy, Asthma, & Urticaria
  • Principal Investigator: Joseph Flanagan, MD, Health Sciences Research Center
  • Principal Investigator: Brad H Goodman, MD, Aeroallergy Research Laboratories
  • Principal Investigator: Frank Hampel, MD, Central Texas Allergy and Asthma
  • Principal Investigator: Yu-Luen Hsu, MD, West Coast Clinical Trials Phase 2-4
  • Principal Investigator: Neil Kao, MD, Allergic Disease and Asthma Cente
  • Principal Investigator: John Prestigiacomo, MD, Gulf Coast Research Associates, Inc
  • Principal Investigator: Christopher Smith, MD, Asthma and Allergy Associates, P.C.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2008

Primary Completion (Actual)

December 1, 2008

Study Registration Dates

First Submitted

November 17, 2008

First Submitted That Met QC Criteria

November 18, 2008

First Posted (Estimate)

November 19, 2008

Study Record Updates

Last Update Posted (Estimate)

March 4, 2010

Last Update Submitted That Met QC Criteria

February 23, 2010

Last Verified

February 1, 2010

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allergic Rhinitis

Clinical Trials on Olopatadine Hydrochloride Nasal Spray 0.6%

Subscribe